Antimicrobial susceptibility testing in 90min by bacterial cell count monitoring

Clinical Microbiology and Infection

Volumn 19, Issue 3, 2013, Pages 286-291

  Broeren, M A C ^a   Maas, Y ^b   Retera, E ^b   Arents, N L A ^b  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b Stichting Laboratoria voor Pathologie en Medische Microbiologie   (Netherlands)

Author keywords

Antibiotics; Cell count monitoring; Flow cytometry; Microbiology; Susceptibility testing

Indexed keywords

AMOXICILLIN; GENTAMICIN; PIPERACILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BROTH DILUTION; CELL COUNT; CONTROLLED STUDY; EPSILOMETER TEST; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84874331667     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03800.x     Document Type: Article

References (15)

1. Smith RD, Coast J. Antimicrobial resistance: a global response. Bull World Health Organ 2002; 80: 126-133.
2. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
3. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
4. Infectious Disease Society of America. Bad bugs, no drugs. As antibiotic discovery stagnates, a public health crisis brews. White paper. Alexandria: Infectious Disease Society of America, 2004; 1-35.
5. Eigner U, Schmid A, Wild U, Bertsch D, Fahr AM. Analysis of the comparative workflow and performance characteristics of the VITEK 2 and phoenix systems. J Clin Microbiol 2005; 43: 3829-3834.
6. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-268.
7. Trenholme GM, Kaplan RL, Karakusis PH et al. Clinical impact of rapid identification and susceptibility testing of bacterial blood culture isolates. J Clin Microbiol 1989; 27: 1342-1345.
8. Steen HB, Boye E, Skarstad K, Bloom B, Gordal T, Mustafa S. Application of flow cytometry on bacteria: cell cycle kinetics, drug effects, and quantitation of antibody binding. Cytometry 1982; 2: 249-257.
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th edn. Approved Standard M07-A8. Wayne: Clinical and Laboratory Standards Institute, 2009; 1-70.
10. U.S. Department of Health and Human Services Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. Rockville: Guidance for Industry and FDA, 2009.
11. Alvarez-Barrientos A, Arroyo J, Canton R, Nombela C, Sanchez-Perez M. Applications of flow cytometry to clinical microbiology. Clin Microbiol Rev 2000; 13: 167-195.
12. Walberg M, Gaustad P, Steen HB. Rapid flow cytometric assessment of mecillinam and ampicillin bacterial susceptibility. J Antimicrob Chemother 1996; 37: 1063-1075.
13. Mason DJ, Gant VA. The application of flow cytometry to the estimation of bacterial antibiotic susceptibility. J Antimicrob Chemother 1995; 39: 441-443.
14. Cohen CY, Sahar E. Rapid flow cytometric bacterial detection and determination of susceptibility to amikacin in body fluids and exudates. J Clin Microbiol 1989; 27: 1250-1256.
15. Malleo D, Nevill JT, Lee LP, Morgan H. Continuous differential impedance spectroscopy of single cells. Microfluid Nanofluidics 2010; 9: 191-198.